Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer

Early Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 754091
Drug: BI 754111

First Posted Date: 2018-02-15

Last Posted Date: 2023-07-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 146

Registration Number: NCT03433898

Locations: 🇯🇵
Kanagawa Cancer Center, Kanagawa, Yokohama, Japan
🇯🇵
Japanese Foundation for Cancer Research, Tokyo, Koto-ku, Japan
🇯🇵
National Cancer Center Hospital East, Chiba, Kashiwa, Japan

and more 10 locations

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Metformin
Drug: Insulin
Drug: Placebo
Drug: Linagliptin
Drug: Empagliflozin

First Posted Date: 2018-02-12

Last Posted Date: 2024-02-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 175

Registration Number: NCT03429543

Locations: 🇺🇸
Children's Center for Advanced Pediatrics, Atlanta, Georgia, United States
🇺🇸
Atlanta Center, Atlanta, Georgia, United States
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States

and more 79 locations

Greek NIS Spiolto ELLACTO

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: MaxSpiolto® Respimat® 160 Characters...

First Posted Date: 2018-02-05

Last Posted Date: 2020-04-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1360

Registration Number: NCT03419962

Locations: 🇬🇷
Metropolitan, Patra, Greece
🇬🇷
Metroplitan, Athens, Greece
🇬🇷
Diavalkaniko, Volos, Greece

and more 1 locations

This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.

Phase 1

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: BI 1015550

First Posted Date: 2018-02-05

Last Posted Date: 2019-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT03422068

Locations: 🇪🇸
Hospital de Bellvitge, L'Hospitalet de Llobregat, Spain
🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain
🇬🇧
Southampton General Hospital, Southampton, United Kingdom

and more 10 locations

This Study Tests How Different Doses of BI 1291583 Are Taken up in the Body and How Well They Are Tolerated

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: BI 1291583

First Posted Date: 2018-01-29

Last Posted Date: 2020-11-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 54

Registration Number: NCT03414008

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2018-01-23

Last Posted Date: 2021-04-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 65406

Registration Number: NCT03405363

Locations: 🇩🇰
Aarhus Universitets hospital Skejby, Aarhus, Denmark

This Study in Healthy Men Tests How Itraconazole Influences the Amount of BI 1015550 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1015550
Drug: itraconazole

First Posted Date: 2018-01-18

Last Posted Date: 2018-07-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT03403439

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study

Completed

Conditions: Idiopathic Pulmonary Fibrosis

First Posted Date: 2017-12-29

Last Posted Date: 2020-11-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 204

Registration Number: NCT03386994

Locations: 🇪🇸
Hospital Clínico Universitario de Valladolid, Valladolid, Spain
🇪🇸
H. de Manacor, Mallorca, Spain
🇪🇸
Hospital Costa del Sol, Marbella (Málaga), Spain

and more 28 locations

An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis

Phase 2

Completed

Conditions: Lupus Nephritis

Interventions: Drug: BI 655064
Drug: Placebo

First Posted Date: 2017-12-28

Last Posted Date: 2022-07-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 69

Registration Number: NCT03385564

Locations: 🇬🇷
University General Hospital Attikon, Athens, Greece
🇯🇵
Okayama University Hospital, Okayama, Okayama, Japan
🇲🇽
Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico

and more 33 locations

This Study Tests BI 1467335 in Healthy Male Volunteers. The Study Tests How Different Doses of BI 1467335 Are Taken up and Handled by the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1467335
Drug: [14C]BI 1467335

First Posted Date: 2017-12-26

Last Posted Date: 2021-06-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT03382509

Locations: 🇳🇱
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy